Last week, the municipality of Leiden and local educational institutions organized an alternative protest to show their solidarity. Hundreds of supporters gathered to collectively emphasize: “No innovation without education!” Through a united message, they highlighted the importance of structural support for education, both for the region and the nation as a whole.
Joint Call to the Government
As a knowledge city, we demonstrate that collaboration between education, business, and government is essential for a strong economy. Supported by partners such as Leiden University, LUMC, Leiden University of Applied Sciences, mboRijnland, Naturalis, and companies at the Leiden Bio Science Park such as Johnson & Johnson and Airbus Defence & Space NL, Knowledge City Leiden issued a video message urging the government to reconsider its planned cuts:
“We need a robust education system that trains diverse talent and fosters groundbreaking research with immediate impact. But this vital contribution to our knowledge economy is at risk if the government proceeds with these cuts to education. This comes from a government claiming to prioritize innovation.
That’s why we, as educational institutions, businesses, and the municipality, call on you: keep investing in education, innovation, talent, and research. Only then can we, as a strong knowledge city, maintain our knowledge and innovation strength for the benefit of the Netherlands.”
Knowledge City Leiden
Recently named National Education City 2025, Leiden is known as a hub where education, research institutions, and businesses collaborate on future solutions. From the development of innovative new medicines to technological advancements at the Leiden Bio Science Park, this knowledge positions the Netherlands as an international leader in innovation.
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...
Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown insulin-producing islet cells derived from...
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.